A test measuring circulating tumor cells in the bloodstream was able to accurately detect early-stage colorectal cancers, according to the results of a new study.
Adjuvant everolimus did not improve disease-free survival in patients with DLBCL and confirmed complete response after 1 year of rituximab treatment.
After undergoing treatment, women with young-onset breast cancer and BRCA mutations had similar survival rates as those women who were not mutation carriers, according to the results of a prospective study.
Reduced expression of PBRM1 and VHL was correlated with increased tumor aggressiveness in clear cell renal cell carcinoma, according to the results of a recent study.
Duvelisib improved the median progression-free survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma by about 3.5 months compared with the current standard, ofatumumab.
Only a small percentage of patients undergoing active surveillance for papillary thyroid carcinoma will experience increases in tumor diameter by 3 mm or more during the first 5 years of surveillance.
PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.
Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.
A new study has shown several ways that the health-related quality of life in cancer patients older than 65 years could be improved.
The FDA has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations after complete disease resection.